About Spectrum Pharmaceuticals (NASDAQ:SPPI)
Spectrum Pharmaceuticals, Inc. is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has a product portfolio consisting of both commercial stage and development stage products that address various cancer types. The Company has six approved oncology/hematology products that target different types of cancer, including non-Hodgkin's lymphoma (NHL), advanced metastatic colorectal cancer (mCRC), acute lymphoblastic leukemia (ALL) and multiple myeloma (MM). It also has three drugs in mid-to-late stage development, which include ROLONTIS for chemotherapy-induced neutropenia; QAPZOLA for immediate intravesical instillation in post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer (NMIBC), and POZIOTINIB, a pan-human epidermal growth factor receptor (HER) inhibitor used in the treatment of patients with a range of solid tumors, including breast and lung cancer.
Industry, Sector and Symbol:
- Industry: Biotechnology & Medical Research
- Sub-Industry: Biotechnology
- Sector: Medical
- Symbol: NASDAQ:SPPI
- CUSIP: 84763A10
- Web: www.sppirx.com
- Debt-to-Equity Ratio: 0.33%
- Current Ratio: 5.04%
- Quick Ratio: 4.89%
Sales & Book Value:
- Annual Sales: $146.44 million
- Price / Sales: 13.40
- Book Value: $2.93 per share
- Price / Book: 6.66
- Trailing EPS: ($0.99)
- Net Income: ($68,510,000.00)
- Net Margins: -58.94%
- Return on Equity: -29.73%
- Return on Assets: -16.45%
- Employees: 227
- Outstanding Shares: 100,660,000
Frequently Asked Questions for Spectrum Pharmaceuticals (NASDAQ:SPPI)
What is Spectrum Pharmaceuticals' stock symbol?
Spectrum Pharmaceuticals trades on the NASDAQ under the ticker symbol "SPPI."
How were Spectrum Pharmaceuticals' earnings last quarter?
Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) posted its quarterly earnings data on Thursday, November, 2nd. The biotechnology company reported ($0.22) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.16) by $0.06. The biotechnology company had revenue of $36.40 million for the quarter, compared to the consensus estimate of $33.27 million. Spectrum Pharmaceuticals had a negative net margin of 58.94% and a negative return on equity of 29.73%. The business's revenue for the quarter was up 9.0% on a year-over-year basis. During the same quarter last year, the business posted ($0.07) EPS. View Spectrum Pharmaceuticals' Earnings History.
Where is Spectrum Pharmaceuticals' stock going? Where will Spectrum Pharmaceuticals' stock price be in 2017?
4 brokers have issued twelve-month price objectives for Spectrum Pharmaceuticals' shares. Their predictions range from $11.00 to $32.00. On average, they anticipate Spectrum Pharmaceuticals' share price to reach $24.25 in the next twelve months. View Analyst Ratings for Spectrum Pharmaceuticals.
What are Wall Street analysts saying about Spectrum Pharmaceuticals stock?
Here are some recent quotes from research analysts about Spectrum Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Spectrum's low product sales remain a cause of concern. Moreover, gaining market share is challenging for Spectrum as it competes with several companies with greater financial strength. However, the company’s lead pipeline candidate, Rolontis, is progressing well. A BLA is expected in 2018 and a potential approval will help the company compete better. However, Spectrum’s efforts to gain approval for Qapzola (bladder cancer) in the U.S. suffered a setback with the FDA issuing a complete response letter (CRL) in Nov 2016. Additional issues on the regulatory/development front could affect the stock. Also, low product sales remain a cause of concern. On the flip side, with the company entering into out-licensing agreements for a number of products, it will now be able to focus on Evomela and the development of its pipeline candidates. Spectrum’s shares have significantly outperformed the industry so far this year." (10/4/2017)
- 2. Jefferies Group LLC analysts commented, "SPPI is undervalued based on Rolontis' LT promise in chemotherapy-induced neutropenia. We see 50%+ share upside as Rolontis' Ph. III program is lower risk (with data in H1 2018) and we believe its profile, senior management's oncology experience, and CIN market dynamics should enable Rolontis to gain meaningful market share from Neulasta. Poziotinib in mBC/NSCLC bears watching and offers pipeline optionality. Assume at Buy and $7.50 PT." (2/10/2017)
Are investors shorting Spectrum Pharmaceuticals?
Spectrum Pharmaceuticals saw a decrease in short interest in the month of October. As of October 13th, there was short interest totalling 7,292,149 shares, a decrease of 18.1% from the September 29th total of 8,909,100 shares. Based on an average daily trading volume, of 1,684,522 shares, the short-interest ratio is currently 4.3 days. Currently, 9.0% of the company's shares are sold short.
Who are some of Spectrum Pharmaceuticals' key competitors?
Some companies that are related to Spectrum Pharmaceuticals include FibroGen (FGEN), Sage Therapeutics (SAGE), ACADIA Pharmaceuticals (ACAD), Shire Viropharma (VPHM), WuXi PharmaTech (Cayman) (WX), Portola Pharmaceuticals (PTLA), Ligand Pharmaceuticals Incorporated (LGND), Blueprint Medicines Corporation (BPMC), Ironwood Pharmaceuticals (IRWD), Foundation Medicine (FMI), Immunomedics (IMMU), Global Blood Therapeutics (GBT), Intrexon Corporation (XON), Genus plc (GNS), Medpace Holdings (MEDP), Esperion Therapeutics (ESPR), Editas Medicine (EDIT) and Momenta Pharmaceuticals (MNTA).
Who are Spectrum Pharmaceuticals' key executives?
Spectrum Pharmaceuticals' management team includes the folowing people:
- Rajesh C. Shrotriya M.D., Chairman of the Board, Chief Executive Officer (Age 73)
- Joseph W. Turgeon, President, Chief Operating Officer (Age 59)
- Kurt A. Gustafson, Chief Financial Officer, Executive Vice President (Age 49)
- Luigi Lenaz M.D., Lead Independent Director (Age 76)
- Gilles R. Gagnon, Director (Age 63)
- Raymond Wayne Cohen, Independent Director (Age 58)
- Stuart Mitchell Krassner, Independent Director (Age 81)
- Anthony E. Maida III, Ph.D., Independent Director (Age 65)
Who owns Spectrum Pharmaceuticals stock?
Spectrum Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include
SHROTRIYA RAJESH C MD
(8.89%), Dimensional Fund Advisors LP (2.53%), Macquarie Group Ltd. (1.47%), Wells Fargo & Company MN (0.94%), Bank of New York Mellon Corp (0.91%) and Principal Financial Group Inc. (0.75%). View Institutional Ownership Trends for Spectrum Pharmaceuticals.
Who sold Spectrum Pharmaceuticals stock? Who is selling Spectrum Pharmaceuticals stock?
Spectrum Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Macquarie Group Ltd., Dimensional Fund Advisors LP, Cornerstone Capital Management Holdings LLC., Granite Investment Partners LLC, California State Teachers Retirement System, State of Tennessee Treasury Department and Pinebridge Investments L.P.. View Insider Buying and Selling for Spectrum Pharmaceuticals.
Who bought Spectrum Pharmaceuticals stock? Who is buying Spectrum Pharmaceuticals stock?
Spectrum Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including WINTON GROUP Ltd, Wells Fargo & Company MN, Fisher Asset Management LLC, OxFORD Asset Management LLP, Schwab Charles Investment Management Inc., JPMorgan Chase & Co., ClariVest Asset Management LLC and Principal Financial Group Inc.. View Insider Buying and Selling for Spectrum Pharmaceuticals.
How do I buy Spectrum Pharmaceuticals stock?
Shares of Spectrum Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Spectrum Pharmaceuticals' stock price today?
One share of Spectrum Pharmaceuticals stock can currently be purchased for approximately $19.50.
How big of a company is Spectrum Pharmaceuticals?
Spectrum Pharmaceuticals has a market capitalization of $1.96291 billion and generates $146.44 million in revenue each year. The biotechnology company earns ($68,510,000.00) in net income (profit) each year or ($0.99) on an earnings per share basis. Spectrum Pharmaceuticals employs 227 workers across the globe.
How can I contact Spectrum Pharmaceuticals?
Spectrum Pharmaceuticals' mailing address is 11500 SOUTH EASTERN AVENUE SUITE 240, HENDERSON NV, 89052. The biotechnology company can be reached via phone at 702-835-6300 or via email at [email protected]
MarketBeat Community Rating for Spectrum Pharmaceuticals (NASDAQ SPPI)MarketBeat's community ratings are surveys of what our community members think about Spectrum Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Spectrum Pharmaceuticals (NASDAQ:SPPI) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 4 Buy Ratings, 0 Strong Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$24.25 (24.36% upside)|
Consensus Price Target History for Spectrum Pharmaceuticals (NASDAQ:SPPI)
Analysts' Ratings History for Spectrum Pharmaceuticals (NASDAQ:SPPI)
(Data available from 11/20/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|11/3/2017||HC Wainwright||Reiterated Rating||Buy||N/A|
|10/20/2017||Jefferies Group LLC||Boost Price Target||Buy||$25.00||N/A|
|4/1/2017||FBR & Co||Reiterated Rating||Buy||Medium|
|9/15/2016||Royal Bank Of Canada||Set Price Target||Buy||$11.00 -> $10.00||N/A|
Earnings History and Estimates Chart for Spectrum Pharmaceuticals (NASDAQ:SPPI)
Earnings History by Quarter for Spectrum Pharmaceuticals (NASDAQ SPPI)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/2/2017||Q3 2017||($0.16)||($0.22)||$33.27 million||$36.40 million||View||N/A|
|8/3/2017||Q2 2017||($0.27)||($0.26)||$30.50 million||$34.30 million||View||Listen|
|5/2/2017||Q1 2017||($0.20)||($0.18)||$32.23 million||$29.10 million||View||Listen|
|3/8/2017||Q4 2016||($0.27)||($0.22)||$31.13 million||$35.24 million||View||Listen|
|11/14/2016||Q3 2016||($0.30)||($0.22)||$29.53 million||$33.39 million||View||N/A|
|8/9/2016||Q216||($0.29)||($0.05)||$30.88 million||$33.90 million||View||N/A|
|5/5/2016||Q1||($0.32)||($0.14)||$28.83 million||$43.90 million||View||N/A|
|3/9/2016||Q415||($0.18)||($0.06)||$33.87 million||$50.30 million||View||N/A|
|11/4/2015||Q315||($0.25)||($0.28)||$31.87 million||$28.46 million||View||N/A|
|8/6/2015||Q215||($0.22)||($0.01)||$34.48 million||$44.98 million||View||N/A|
|5/7/2015||Q115||($0.06)||($0.07)||$48.00 million||$38.60 million||View||N/A|
|3/13/2015||Q414||($0.16)||$0.09||$48.50 million||$51.70 million||View||N/A|
|11/6/2014||Q314||($0.17)||$0.08||$45.00 million||$47.99 million||View||N/A|
|8/7/2014||Q214||($0.09)||$0.09||$41.50 million||$46.90 million||View||Listen|
|5/8/2014||Q114||($0.22)||$0.01||$39.49 million||$40.10 million||View||Listen|
|3/6/2014||Q313||($0.11)||$0.05||$41.96 million||$41.50 million||View||Listen|
|11/12/2013||Q3||($0.07)||($0.13)||$38.70 million||$42.44 million||View||Listen|
|8/7/2013||Q2 2013||($0.12)||($0.08)||$33.41 million||$33.23 million||View||N/A|
|11/7/2012||Q312||$0.29||$0.42||$68.56 million||$69.00 million||View||N/A|
Earnings Estimates for Spectrum Pharmaceuticals (NASDAQ:SPPI)
2017 EPS Consensus Estimate: ($0.91)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History by Quarter for Spectrum Pharmaceuticals (NASDAQ SPPI)
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Latest Headlines for Spectrum Pharmaceuticals (NASDAQ SPPI)
|Financial Survey: Spectrum Pharmaceuticals (SPPI) versus Its Competitors|
www.americanbankingnews.com - November 20 at 1:30 AM
|Today’s Research Reports on Trending Tickers: Spectrum Pharmaceuticals and Myriad Genetics|
finance.yahoo.com - November 18 at 8:57 AM
|Spectrum Pharmaceuticals, Inc. (SPPI) Expected to Announce Quarterly Sales of $33.05 Million|
www.americanbankingnews.com - November 17 at 10:26 AM
|Spectrum Pharmaceuticals, Inc. (SPPI) Expected to Announce Earnings of -$0.25 Per Share|
www.americanbankingnews.com - November 15 at 11:41 AM
|Why Spectrum Pharmaceuticals Stock Soared in October|
www.fool.com - November 8 at 12:19 PM
|Spectrum (SPPI) Earnings, Sales Beat Q3 Estimates - Nasdaq|
www.nasdaq.com - November 5 at 2:41 AM
|Spectrum Pharmaceuticals, Inc. (SPPI) Stock Rating Reaffirmed by HC Wainwright|
www.americanbankingnews.com - November 4 at 11:32 PM
|Spectrum Pharmaceuticals, Inc. to Host Earnings Call|
finance.yahoo.com - November 4 at 4:39 PM
|Spectrum Pharmaceuticals Reports Third Quarter 2017 Financial Results and Pipeline Update|
finance.yahoo.com - November 4 at 4:39 PM
|Spectrum Pharma reports 3Q loss|
finance.yahoo.com - November 4 at 4:38 PM
|Edited Transcript of SPPI earnings conference call or presentation 2-Nov-17 8:30pm GMT|
finance.yahoo.com - November 4 at 4:38 PM
|Spectrum Pharmaceuticals, Inc. (SPPI) Issues Earnings Results|
www.americanbankingnews.com - November 3 at 4:02 PM
|Spectrum Pharmaceuticals, Inc. (SPPI) Receives Average Recommendation of "Buy" from Analysts|
www.americanbankingnews.com - November 2 at 9:44 PM
|Spectrum Pharmaceuticals (SPPI) Q3 Earnings: What's in Store?|
www.zacks.com - November 2 at 9:06 AM
|Spectrum Pharmaceuticals Announces Third Quarter 2017 Financial Results Teleconference and Webcast|
finance.yahoo.com - October 28 at 6:55 AM
|Short Interest in Spectrum Pharmaceuticals, Inc. (SPPI) Decreases By 18.1%|
www.americanbankingnews.com - October 27 at 1:40 AM
|Zacks: Analysts Expect Spectrum Pharmaceuticals, Inc. (SPPI) Will Announce Earnings of -$0.23 Per Share|
www.americanbankingnews.com - October 25 at 11:30 PM
|Spectrum Pharmaceuticals, Inc. (SPPI) Now Covered by Analysts at Guggenheim|
www.americanbankingnews.com - October 23 at 6:50 PM
|Critical Survey: Spectrum Pharmaceuticals (SPPI) vs. Its Peers|
www.americanbankingnews.com - October 22 at 8:20 AM
|Jefferies Group LLC Raises Spectrum Pharmaceuticals, Inc. (SPPI) Price Target to $25.00|
www.americanbankingnews.com - October 21 at 2:58 PM
|Spectrum Pharmaceuticals Inc. (SPPI) Leaped To A New High On Phase 2 Study News|
www.rttnews.com - October 20 at 8:22 AM
|Spectrum Pharmaceuticals Inc. (SPPI) Has Surged To A New High On Study Results - Nasdaq|
www.nasdaq.com - October 19 at 9:10 AM
|Spectrum Pharmaceuticals, Inc. (SPPI) Receives Buy Rating from HC Wainwright|
www.americanbankingnews.com - October 18 at 7:08 PM
|Jefferies Group Weighs in on Spectrum Pharmaceuticals, Inc.'s Q3 2017 Earnings (SPPI)|
www.americanbankingnews.com - October 11 at 6:08 AM
|Jefferies Group LLC Boosts Spectrum Pharmaceuticals, Inc. (SPPI) Price Target to $18.00|
www.americanbankingnews.com - October 9 at 10:38 AM
|HC Wainwright Boosts Spectrum Pharmaceuticals, Inc. (SPPI) Price Target to $20.00|
www.americanbankingnews.com - October 9 at 12:28 AM
|Spectrum Pharmaceuticals, Inc. (SPPI) Downgraded to "Sell" at Zacks Investment Research|
www.americanbankingnews.com - October 8 at 6:40 PM
|Spectrum Pharmaceuticals, Inc. (SPPI) Given Average Rating of "Buy" by Analysts|
www.americanbankingnews.com - October 8 at 6:38 PM
|Spectrum Pharmaceuticals, Inc. (SPPI) Expected to Announce Quarterly Sales of $34.40 Million|
www.americanbankingnews.com - October 8 at 1:02 AM
|-$0.22 Earnings Per Share Expected for Spectrum Pharmaceuticals, Inc. (SPPI) This Quarter|
www.americanbankingnews.com - October 7 at 12:18 AM
|BRIEF-Spectrum Pharmaceuticals provides update on at-the-market facility|
www.reuters.com - September 30 at 11:24 AM
|Spectrum Pharma (SPPI) Says it Issued Approximately 9.3M Shares of Common Stock Under Previously Announced At-The-Market Facility|
www.streetinsider.com - September 30 at 11:24 AM
|Spectrum Pharmaceuticals Provides Update On At-The-Market Facility|
www.thestreet.com - September 30 at 11:24 AM
|Spectrum Pharma (SPPI) Says Poziotinib Data in Lung Cancer to be Presented at IASLC - StreetInsider.com|
www.streetinsider.com - September 29 at 7:02 AM
|Q3 2017 Earnings Estimate for Spectrum Pharmaceuticals, Inc. Issued By Jefferies Group (SPPI)|
www.americanbankingnews.com - September 27 at 8:00 AM
|Jefferies Group Research Analysts Reduce Earnings Estimates for Spectrum Pharmaceuticals, Inc. (SPPI)|
www.americanbankingnews.com - September 26 at 3:24 PM
|Reviewing Compugen (CGEN) and Spectrum Pharmaceuticals (SPPI)|
www.americanbankingnews.com - September 17 at 10:32 PM
|HC Wainwright Reiterates "Buy" Rating for Spectrum Pharmaceuticals, Inc. (SPPI)|
www.americanbankingnews.com - September 14 at 4:18 PM
|Spectrum Pharmaceuticals, Inc. (SPPI) Receives Average Rating of "Buy" from Brokerages|
www.americanbankingnews.com - September 13 at 8:54 PM
|Comparing Spectrum Pharmaceuticals (SPPI) and Portola Pharmaceuticals (PTLA)|
www.americanbankingnews.com - September 10 at 3:02 PM
|Spectrum Pharmaceuticals to Present at Two Upcoming Investor Conferences in September - Business Wire (press release)|
www.businesswire.com - September 5 at 9:40 PM
|Advaxis (ADXS) & Spectrum Pharmaceuticals (SPPI) Critical Review|
www.americanbankingnews.com - September 5 at 6:04 PM
| Brokerages Anticipate Spectrum Pharmaceuticals, Inc. (SPPI) Will Announce Quarterly Sales of $34.40 Million|
www.americanbankingnews.com - September 1 at 3:26 AM
|Spectrum Pharmaceuticals, Inc. (SPPI) Expected to Post Earnings of -$0.23 Per Share|
www.americanbankingnews.com - August 30 at 6:16 PM
|Spectrum Pharmaceuticals, Inc. (SPPI) Given a $9.00 Price Target at Jefferies Group LLC|
www.americanbankingnews.com - August 26 at 8:16 AM
|HC Wainwright Reiterates Buy Rating for Spectrum Pharmaceuticals, Inc. (SPPI)|
www.americanbankingnews.com - August 21 at 12:34 AM
|Spectrum Pharma (SPPI) Reports Initiation of Registrational Phase 3 Trial of Qapzola in Patients with Non-Muscle ... - StreetInsider.com|
www.streetinsider.com - August 15 at 7:12 AM
|Spectrum Pharmaceuticals Announces Initiation of the Registrational Phase 3 Trial of Qapzola™ (apaziquone) in Patients with Non-Muscle Invasive Bladder Cancer (NMIBC)|
finance.yahoo.com - August 15 at 7:12 AM
|Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Expected to Announce Quarterly Sales of $29.86 Million|
www.americanbankingnews.com - August 14 at 9:52 AM
|Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPS|
www.americanbankingnews.com - August 5 at 12:46 AM
Spectrum Pharmaceuticals (NASDAQ SPPI) Chart for Monday, November, 20, 2017